OCA
ITOS

Octagon Capital Advisors’s iTeos Therapeutics ITOS Stock Holding History

Octagon Capital Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-102,000
Closed -$1.12M – 41
2023
Q3 		$1.12M Sell
102,000
-494,000
-83% -$6.32M 0.17% 37
2023
Q2 		$7.89M Hold
596,000
– – 1.1% 16
2023
Q1 		$8.11M Buy
596,000
+151,000
+34% +$2.71M 1.17% 17
2022
Q4 		$8.69M Buy
+445,000
New +$8.7M 1.35% 17
2022
Q2 		– Sell
-450,776
Closed -$14.5M – 23
2022
Q1 		$14.5M Hold
450,776
– – 3.14% 11
2021
Q4 		$21M Buy
+450,776
New +$15M 4.08% 7

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Octagon Capital Advisors's ITOS Position: Q4 2023 in Review

Octagon Capital Advisors sold out of iTeos Therapeutics (ITOS) in Q4 2023, closing a stake of 102,000 shares — an estimated $1.12M sold.

Octagon Capital Advisors first reported a position in ITOS in Q4 2021 and held it in 6 quarters. The position peaked at $21M in Q4 2021. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2023.

  • Octagon Capital Advisors reported no remaining iTeos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Octagon Capital Advisors sold 102,000 iTeos Therapeutics shares in Q4 2023, an estimated $1.12M.
  • Octagon Capital Advisors first reported a position in iTeos Therapeutics in Q4 2021 and held it in 6 quarters.
  • Octagon Capital Advisors's iTeos Therapeutics position peaked at $21M in Q4 2021.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2023.

Based on Octagon Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.